This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.
Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. Our product pipeline includes:
PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.
PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read detailed Research Reports
Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com
August 19, 2008
PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia
The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
pvct.com
PVCT on YouTube...
youtube.com
theze.cn
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.
pvct.com
This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
pvct.com
--------------------------------------------------------------
Contact Info
Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907
Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229
jkessler@investorrelationsgroup.com
Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210
janet@theinvestorrelationsgroup.com
--------------------------------------------------------------
Company Website
pvct.com
==============================================================
Clinical Trials
Melanoma Phase I
clinicaltrials.gov
Melanoma Phase II
clinicaltrials.gov.
Breast Carcinoma Phase I - Completion Dec 2007
clinicaltrials.gov
National Cancer Institute Link - Breast Cancer
cancer.gov.
National Cancer Institute Link - Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
cancer.gov |
